Summary
A systematic review and meta-analysis published in the BMJ on January 7, 2026 examined what happens to body weight and cardiometabolic health markers in the months and years after people stop taking weight-loss medications. The research was led by Dr. Sam West, a postdoctoral researcher at the Nuffield Department of Primary Care Health Sciences at the University of Oxford, with Associate Professor Dimitrios Koutoukidis and Professor Susan Jebb as senior authors. The study was funded by the National Institute for Health and Care Research (NIHR) Oxford Biomedical Research Centre.
The review pooled data from 37 studies involving 9,341 participants across 13 different weight-loss medications, ranging from older drugs like orlistat to the newer GLP-1 receptor agonists semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro). Participants were tracked for an average of 32 weeks after stopping medication, following an average treatment period of 39 weeks. Three separate analytical approaches were applied, all producing consistent results.
DOI: 10.1136/bmj-2025-085304
PMID: PMC12776922
Across all 37 studies, weight increased by an average of 0.4 kg per month after stopping weight-loss drugs. At that rate, researchers estimate participants would return to their pre-treatment starting weight within 1.5 to 2 years. For the newer medications, semaglutide and tirzepatide specifically, the rate was higher: 0.8 kg per month, with projections indicating full return to baseline within approximately 18 months.
The comparison with behavioral interventions is the most significant finding. Weight regain after stopping drugs was approximately four times faster than after ending diet and physical activity programs and critically, this differential held regardless of how much weight was initially lost. Even patients who had achieved substantial weight loss on GLP-1 drugs regained weight faster than patients who had lost the same amount through diet and exercise alone. Behavioral support provided alongside medication was associated with greater weight loss during treatment but did not slow the rate of regain once medication stopped.
All cardio metabolic health improvements also reversed following discontinuation. HbA1c, fasting glucose, blood pressure, cholesterol, and triglyceride levels, which had all improved during treatment, are estimated to return to baseline within approximately 1.4 years after stopping.
The findings arrive in a context worth noting: around half of all people prescribed GLP-1 receptor agonists discontinue treatment within 12 months, and approximately nine in ten people currently using these medications in the UK are purchasing them privately often without the comprehensive clinical oversight and behavioral support that accompanies NHS prescribing.
The mechanism behind this finding is straightforward. GLP-1 receptor agonists work by pharmacologically mimicking a hormone the body produces naturally in response to food, particularly protein, to generate satiety, slow gastric emptying, and regulate blood glucose. When the drug is removed, the signal disappears entirely. The body has not developed any new physiological capacity for producing or sustaining that signal on its own. What the drug provided was borrowed biology.
Behavioral interventions, even imperfect ones, require the person to actively change how they eat, how they move, and how they respond to hunger. Those adaptations leave traces: changed habits, modified food environments, some degree of learned appetite regulation. The drug leaves none of that behind when it is stopped. The fourfold difference in regain rate is the quantification of that gap.
This is not an argument that GLP-1 drugs don't work. They clearly do, within the treatment window. It is an argument about what "working" means in the context of a chronic condition that does not resolve when a course of medication ends. The question the study implicitly raises is whether the body can be supported to produce and sustain its own GLP-1 signal through the food it receives, rather than relying on a pharmaceutical substitute that requires indefinite use to maintain its effects.
Sources
- West S, Jebb S, et al. — Weight regain after cessation of medication for weight management: systematic review and meta-analysis — BMJ, January 7, 2026 — DOI: 10.1136/bmj-2025-085304
- BMJ Group press release: https://bmjgroup.com/stopping-weight-loss-drugs-linked-to-weight-regain-and-reversal-of-heart-health-markers/